NCT00847808已完成3 期
A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of Dexlansoprazole MR 30 mg in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy
Takeda0 个研究点目标入组 178 人开始时间: 2009年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 178
- 主要终点
- Proportion of Participants Who Remain Well Controlled After Switching From Their Current Twice-daily Proton Pump Inhibitor Therapy to Dexlansoprazole MR.
研究概览
简要总结
The purpose of this study is to determine if patients with well-controlled heartburn symptoms on twice-daily proton pump inhibitor therapy remain well-controlled after stepping down to once-daily (QD) dexlansoprazole modified release (MR) 30 mg.
详细描述
Gastroesophageal reflux disease is recognized as a common and persistent medical problem in the US adult population. Gastroesophageal reflux disease comprises a spectrum of acid-related disorders including symptomatic nonerosive gastroesophageal reflux disease and erosive esophagitis. It affects men and women in nearly equal proportions, and the severity and intensity of heartburn symptoms may be similar in both types of patients.
Dexlansoprazole modified release is a dual delayed release formulation that consists of two types of granules contained in a single capsule. This dual delayed release formulation is designed to extend the duration of drug exposure and maintain pharmacologically active levels over a longer time period.
The purpose of this study is to demonstrate that participants with gastroesophageal reflux disease whose symptoms are well-controlled on twice daily proton pump inhibitors, remain well-controlled when switched to dexlansoprazole MR.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Prior to any study-specific procedures being performed, the participant voluntarily signs an Investigational Review Board-approved informed consent form (ICF) and any privacy statement/authorization form required (eg, The Health Insurance Portability and Accountability Act (HIPAA) authorization)
- •Has a history of gastroesophageal reflux disease symptom, including heartburn, prior to therapy, who are currently being treated with twice daily proton pump inhibitors, excluding Dexilant (dexlansoprazole).
- •Taking a stable dose of any twice daily proton pump inhibitors for less than or equal to 1 year and greater than 8 weeks prior to Screening.
- •Participant is well-controlled on their current twice daily proton pump inhibitors.
- •Females cannot be nursing and must have a negative urine pregnancy test at Day -1 or be of non-childbearing potential. If females are of child bearing potential, must have a negative serum human chorionic gonadotropin (hCG) pregnancy test during Screening and on an acceptable form of contraception, or have had bilateral tubal ligation if performed a minimum of 90 days prior to Day 1.
排除标准
- •Has a history of co-existing diseases affecting the esophagus, history of radiation therapy or cryotherapy to the esophagus, caustic or physiochemical trauma such as sclerotherapy to the esophagus.
- •Has active gastric or duodenal ulcers during the 30 days prior to Screening.
- •Has acute upper gastrointestinal hemorrhage during the 30 days prior to Screening.
- •Has current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition.
- •Has known hypersensitivity to any proton pump inhibitor or any component of dexlansoprazole MR.
- •Use of any Histamine type-2 receptor antagonist or antacids during Screening or anticipated use during the study treatment period.
- •Use of the following medications 7 days prior to Screening or anticipated use during the study:
- •Sucralfate.
- •Misoprostol.
- •Systemic corticosteroids.
- •Prokinetics (to include metoclopramide, cisapride, tegaserod).
- •Bisphosphonates during the 6 months prior to Screening or anticipated use during the study.
- •Chronic use (> 12 doses per month) of nonsteroidal anti-inflammatory drugs
- •Drugs with significant anticholinergic effects such as tricyclic antidepressants or drugs with central nervous system effects that could mask perception of symptoms.
- •Any investigational drug(s) within 30 days of Screening.
- •Has received blood products within the 3 months prior to Screening.
- •History of alcohol abuse or illegal drug use or drug addiction in the 12 months prior to Screening.
- •Evidence of uncontrolled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality, which may impact the ability of the participant to participate or potentially confound the study results.
- •Atypical manifestations of gastroesophageal reflux disease.
- •Has abnormal screening laboratory values that suggest a clinically significant underlying disease or condition.
- •Cancer within 5 years prior to Screening.
- •Is known to have acquired immunodeficiency syndrome.
- •Has any condition that is likely to require inpatient surgery during the course of the study.
- •Surgery of the acute upper gastrointestinal tract, including bariatric.
- •Is in the opinion of the investigator unable to comply with the requirements of the study or are unsuitable for any reason.
研究组 & 干预措施
1
Experimental
干预措施: Dexlansoprazole MR QD (Drug)
结局指标
主要结局
Proportion of Participants Who Remain Well Controlled After Switching From Their Current Twice-daily Proton Pump Inhibitor Therapy to Dexlansoprazole MR.
时间窗: Week 3 through Week 6
Well-controlled participants were defined to be participants who completed the study having at least 23 days of evaluable diary entries between Days 15 and 42, inclusive, and had ≤4 occurrences of heartburn during this period.
次要结局
- Change From Baseline in the Patient Assessment of Upper Gastrointestinal Disorders - Quality of Life (PAGI-QOL) - Daily Activities Subscale in Participants Who Remain Well-controlled.(Baseline and Week 6.)
- Change From Baseline in the Patient Assessment of Upper Gastrointestinal Disorders - Quality of Life (PAGI-QOL) - Clothing Subscale in Participants Who Remain Well-controlled.(Baseline and Week 6.)
- Change From Baseline in the Patient Assessment of Upper Gastrointestinal Disorders - Quality of Life (PAGI-QOL) - Diet and Food Habits Subscale in Participants Who Remain Well-controlled.(Baseline and Week 6.)
- Change From Baseline in the Patient Assessment of Upper Gastrointestinal Disorders - Quality of Life (PAGI-QOL) - Relationship Subscale in Participants Who Remain Well-controlled.(Baseline and Week 6.)
- Change From Baseline in the Patient Assessment of Upper Gastrointestinal Disorders - Quality of Life (PAGI-QOL) - Psychological Well-being Subscale in Participants Who Remain Well-controlled.(Baseline and Week 6.)
- Change From Baseline in the Patient Assessment of Upper Gastrointestinal Disorders - Quality of Life (PAGI-QOL) - Total Score in Participants Who Remain Well-controlled.(Baseline and Week 6.)
- Change From Baseline in Patient Assessment of Upper Gastrointestinal Disorders - Symptom Severity Index (PAGI-SYM) - Nausea/Vomiting Subscale in Participants Who Remain Well-controlled.(Baseline and Week 6.)
- Change From Baseline in Patient Assessment of Upper Gastrointestinal Disorders - Symptom Severity Index (PAGI-SYM) - Fullness/Early Satiety Subscale in Participants Who Remain Well-controlled.(Baseline and Week 6.)
- Change From Baseline in Patient Assessment of Upper Gastrointestinal Disorders - Symptom Severity Index (PAGI-SYM) - Bloating Subscale in Participants Who Remain Well-controlled.(Baseline and Week 6.)
- Change From Baseline in Patient Assessment of Upper Gastrointestinal Disorders - Symptom Severity Index (PAGI-SYM) - Upper Abdominal Pain Subscale in Participants Who Remain Well-controlled.(Baseline and Week 6.)
- Change From Baseline in Patient Assessment of Upper Gastrointestinal Disorders - Symptom Severity Index (PAGI-SYM) - Lower Abdominal Pain Subscale in Participants Who Remain Well-controlled.(Baseline and Week 6.)
- Change From Baseline in Patient Assessment of Upper Gastrointestinal Disorders - Symptom Severity Index (PAGI-SYM) - Heartburn/Regurgitation Subscale in Participants Who Remain Well-controlled.(Baseline and Week 6.)
- Change From Baseline in Patient Assessment of Upper Gastrointestinal Disorders - Symptom Severity Index (PAGI-SYM) - Total Score in Participants Who Remain Well-controlled.(Baseline and Week 6.)
研究者
相似试验
已完成
3 期
A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic ArthritisArthritis, PsoriaticNCT01009086Janssen Research & Development, LLC615
终止
3 期
Tecfidera Slow-Titration StudyMultiple SclerosisNCT02428231Biogen62
已完成
3 期
Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)Attention Deficit Hyperactivity Disorder (ADHD)NCT03260205Shire199
已完成
3 期
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeSjogren SyndromeNCT05350072Novartis Pharmaceuticals275
撤回
3 期
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)Thymidine Kinase 2 DeficiencyNCT04581733Zogenix MDS, Inc.